{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:44:44Z","timestamp":1791236684242,"version":"4.1.0"},"reference-count":0,"publisher":"IMR Press","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Low-density lipoprotein (LDL) receptors on the surface of liver hepatocytes are the primary way that humans regulate serum LDL cholesterol levels. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is a proteolytic enzyme that indirectly regulates serum LDL cholesterol (LDL-C) by causing the destruction of LDL receptors. Less LDL receptors result in increased LDL-C in the bloodstream but inhibiting or binding the circulating PCSK9 results in increased LDL receptors with the resultant decrease in serum LDL-C. Two PCSK9 inhibitors are currently approved for use: alirocumab and evolocumab. Both are fully human monoclonal antibodies that bind free PCSK9. Herein we discuss the mechanism of action, efficacy, and safety of PCSK9 inhibitors.<\/jats:p>","DOI":"10.3909\/ricm19s1s0002","type":"journal-article","created":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T20:59:00Z","timestamp":1648414740000},"source":"Crossref","is-referenced-by-count":91,"title":["PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety"],"prefix":"10.31083","volume":"19","author":[{"given":"Eli M.","family":"Roth","sequence":"first","affiliation":[{"name":"Sterling Research Group, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2018,1,20]]},"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/19\/S1\/10.3909\/ricm19S1S0002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:53:09Z","timestamp":1732708389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/19\/S1\/10.3909\/ricm19S1S0002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,20]]},"references-count":0,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018]]}},"alternative-id":["1550743173858-37649676"],"URL":"https:\/\/doi.org\/10.3909\/ricm19s1s0002","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,20]]},"article-number":"31"}}